YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer

• Main Authors: Fangfang Lai (Author), Ming Ji (Author), Lei Huang (Author), Yunchen Wang (Author), Nina Xue (Author), Tingting Du (Author), Kai Dong (Author), Xiaoqing Yao (Author), Jing Jin (Author), Zhiqiang Feng (Author), Xiaoguang Chen (Author)
• Format: Book
• Published: Elsevier, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

PD-1 and PD-L1 antibodies have brought about extraordinary clinical benefits for cancer patients, and their indications are expanding incessantly. Currently, most PD-1/PD-L1 agents are administered intravenously, which may be uncomfortable for some cancer patients. Herein, we develop a novel oral-de...